Free Trial
NYSE:PFE

Pfizer (PFE) Stock Price, News & Analysis

$27.92
-0.12 (-0.43%)
(As of 07/8/2024 ET)
Today's Range
$27.79
$28.12
50-Day Range
$25.61
$29.60
52-Week Range
$25.20
$37.80
Volume
25.68 million shs
Average Volume
27.59 million shs
Market Capitalization
$158.24 billion
P/E Ratio
N/A
Dividend Yield
6.02%
Price Target
$35.54

Pfizer MarketRank™ Stock Analysis

Analyst Rating
Hold
2.43 Rating Score
Upside/​Downside
27.3% Upside
$35.54 Price Target
Short Interest
Healthy
1.10% of Shares Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.68
Upright™ Environmental Score
News Sentiment
0.67mentions of Pfizer in the last 14 days
Based on 34 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
15.55%
From $2.38 to $2.75 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.94 out of 5 stars

Medical Sector

17th out of 876 stocks

Pharmaceutical Preparations Industry

4th out of 416 stocks

PFE stock logo

About Pfizer Stock (NYSE:PFE)

Pfizer Inc. is a US-based multinational biotech company. The company operates as a research-based pharmaceutical company focused on the discovery, production and marketing of medicines and vaccines. It is the 2nd largest drugmaker globally by revenue and is ranked 64th on the Fortune 500 list. The company’s avenues of research include Immunology, Oncology, Cardiology, Endocrinology and Neurology.

Regarding its product line, the company has at least ten blockbuster drugs producing more than $1 billion in avenue revenue each. The company brought in over $81 billion in total revenue in 2021. The US is its main market and represents roughly 50% of all revenue. China and Japan make up roughly 12% of the business, while the rest come from the “rest of the world”. It employs roughly 79,000 people and is headquartered in New York state.

Pfizer Inc. was founded in 1849 by Charles Pfizer Sr. and his cousin Charles Earhart. The two were German immigrants and chemists that set up shops outside New York City to make medicinal compounds. The first major success was an antiparasitic called santonin, and the commercialization of citric acid-making technologies quickly followed that up. Their success with citric acid led to the company’s expansion and other major discoveries.

World War I caused a shortage of materials for making citric acid and forced the company to seek alternatives. The one they latched on to was the fermentation of certain fungi known to produce citric acid naturally. This led to the advancement of fermentation technology that was later used in the commercial production of penicillin and then the advancement of antibiotics in general.

Pfizer Inc was incorporated on June 2nd, 1942 in Delaware, and another period of expansion began. The postwar drop in demand for penicillin led to the discovery of newer, more marketable antibiotics and cemented the company’s role in modern medicine. By the time he 80s rolled around, the company was trading on the New York Stock Exchange and on the path to developing today’s blockbuster lineup.

The company’s top seller in 2021 was Comirnaty, a COVID-19 vaccine. It generated nearly $37 billion in 2021 and was followed by Prevnar, Ibrance and Eliquis with just over $5 billion in sales each. Other blockbuster names on Pfizer’s list include Xeljanz and Enbrel, each bringing in $3.5 billion. Pfizer operates 39 research and production facilities worldwide and sells its products in 125 countries.

As of 2022, the company had a robust pipeline of potential treatments, with more than 220 in some stage of clinical trials. Among its leading candidates is a vaccine for RSV, a life-threatening respiratory disease affecting children. 2021 highlights include 8 FDA approvals, four new regulatory submissions and 13 new trial startups. Pfizer is also a well-known dividend payer and has returned more than $8.7 billion to shareholders since going public.

 

PFE Stock Price History

PFE Stock News Headlines

Financial markets news icon
MarketBeat Week in Review – 7/1 - 7/5 (PFE)
The market was mostly quiet in a holiday-shortened week; that may change next week with the latest inflation readings and the kickoff of a new earnings season
Businessman and golden bull
3 Stock Giants Analysts Are Bullish On Despite Struggles
Despite their recent struggles, these three industry giants hold the promise of significant upside. With favorable consensus price targets and ratings, attractive P/E valuations, solid earnings growth projections, and some highly attractive dividend yields, they present a hopeful picture for income and value-oriented investors.
Collapse of the Petrodollar
The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.
Businessman and golden bull
3 Stock Giants Analysts Are Bullish On Despite Struggles (PFE)
Despite recent struggles, PYPL, BABA, and PFE present attractive opportunities with favorable P/Es, high dividend yields, and analyst-predicted upsides.
Pharmacist, scientist developing new medicines, medicaments, pharmacy, chemistry
AbbVie Stock: A Perfect Dip for Investors to Buy (PFE)
ABBV stock is down over 3% to start the second half of the year; the stock may be overvalued in the short term but still offers value for long-term investors
syringes, pills, fat
Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer? (PFE)
Clinical-state biopharmaceutical company Altimmune Inc. (NASDAQ: ALT) focuses on developing peptide-based therapeutics for obesity and chronic liver diseases
Logo sign of Pharmaceutical Corporation Pfizer building
Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
Pharmaceutical giant Pfizer Inc. NYSE: PFE has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy makers Novo Nordisk A/S NYSE: NVO and Mounjaro and Zepbound makers Eli Lilly & Co. NYSE: LLY. Pfizer had failed in its previous attempts to create a viable GLP-1 contender.
Logo sign of Pharmaceutical Corporation Pfizer building
Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy
Collapse of the Petrodollar
The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.
mobile phone screen with logo lettering of moderna pharma, stock market chart background
Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines (PFE)
Biotechnology firm Moderna Inc. (NASDAQ: MRNA) made mainstream headlines during the pandemic for its COVID-19 vaccines. Moderna is focused on messenger RNA
Pfizer (NYSE:PFE) Stock Price Down 0.5%
Pfizer: The Inflection Point Is Here
Pfizer (NYSE:PFE) Shares Up 0.5%
See More Headlines
Receive PFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pfizer and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/01/2024
Ex-Dividend for 6/14 Dividend
5/09/2024
Dividend Payable
6/14/2024
Today
7/08/2024
Ex-Dividend for 9/3 Dividend
7/25/2024
Next Earnings (Confirmed)
7/30/2024
Dividend Payable
9/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
CUSIP
71708110
Employees
88,000
Year Founded
1849

Price Target and Rating

Average Stock Price Target
$35.54
High Stock Price Target
$50.00
Low Stock Price Target
$27.00
Potential Upside/Downside
+27.3%
Consensus Rating
Hold
Rating Score (0-4)
2.43
Research Coverage
14 Analysts

Profitability

Net Income
$2.12 billion
Pretax Margin
-3.25%

Debt

Sales & Book Value

Annual Sales
$58.50 billion
Cash Flow
$2.96 per share
Book Value
$15.81 per share

Miscellaneous

Outstanding Shares
5,666,590,000
Free Float
5,663,193,000
Market Cap
$158.24 billion
Optionable
Optionable
Beta
0.69

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Should I Buy Pfizer Stock? PFE Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Pfizer Inc.:

  • Pfizer Inc. has shown consistent growth in its earnings, with analysts raising their Q4 2025 earnings estimates for the company.
  • Positive analyst ratings and target price upgrades indicate confidence in Pfizer's future performance.
  • Pfizer's stock price has been relatively stable, providing a sense of security for investors.
  • Strong financial metrics such as a positive return on equity and a manageable debt-to-equity ratio make Pfizer a financially sound investment.
  • Pfizer's diverse portfolio of pharmaceutical products and ongoing research and development efforts position the company for long-term success in the healthcare industry.

Cons

Investors should be bearish about investing in Pfizer Inc. for these reasons:

  • Recent revenue decline compared to the same quarter last year may raise concerns about Pfizer's ability to sustain growth.
  • The company's negative net margin could indicate potential profitability challenges in the short term.
  • Pfizer's stock performance has been relatively flat, potentially limiting short-term gains for investors.
  • Market volatility and regulatory uncertainties in the pharmaceutical industry could impact Pfizer's stock price unpredictably.
  • Competition from other pharmaceutical companies and potential patent expirations may pose challenges to Pfizer's market share and revenue growth.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, July 7, 2024. Please send any questions or comments about these Pfizer pros and cons to contact@marketbeat.com.

PFE Stock Analysis - Frequently Asked Questions

How have PFE shares performed this year?

Pfizer's stock was trading at $28.79 at the beginning of the year. Since then, PFE stock has decreased by 3.0% and is now trading at $27.9250.
View the best growth stocks for 2024 here
.

How were Pfizer's earnings last quarter?

Pfizer Inc. (NYSE:PFE) released its earnings results on Wednesday, May, 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping analysts' consensus estimates of $0.56 by $0.26. The company's revenue for the quarter was down 19.5% on a year-over-year basis.
Read the conference call transcript
.

What is Albert Bourla's approval rating as Pfizer's CEO?

358 employees have rated Pfizer Chief Executive Officer Albert Bourla on Glassdoor.com. Albert Bourla has an approval rating of 92% among the company's employees. This puts Albert Bourla in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Does Pfizer have any subsidiaries?

Pfizer subsidiaries include ReViral, Arena, Trillium Therapeutics, Amplyx Pharmaceuticals, Array BioPharma, Therachon, Medivation, and others.

Who are Pfizer's major shareholders?

Top institutional shareholders of Pfizer include DNB Asset Management AS (0.03%), Thompson Investment Management Inc. (0.01%), First Financial Bank Trust Division and Massmutual Trust Co. FSB ADV. Insiders that own company stock include Pfizer Inc, William R Carapezzi Jr, Jennifer B Damico, Scott Gottlieb, Alexander R Mackenzie, John D Young and Douglas M Lankler.
View institutional ownership trends
.

How do I buy shares of Pfizer?

Shares of PFE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Pfizer own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pfizer investors own include AT&T (T), Johnson & Johnson (JNJ), Cisco Systems (CSCO), Intel (INTC), Verizon Communications (VZ), AbbVie (ABBV) and Walt Disney (DIS).

This page (NYSE:PFE) was last updated on 7/9/2024 by MarketBeat.com Staff

From Our Partners